Mumbai: Molnupiravir, antivirus drugs that have recently received emergency use for Covid-19 treatment which are light to moderate in India, launched on Monday at Rs 1,399 for a full five-day course, making it one of the cheapest antivirus antivirus therapy during the pandemic.
More than a dozen companies, including Hetero, Sun Pharma, Natco and Dr.
Reddy are in the process of launching oral therapy developed by Merck and their partners, Ridgeback Biotherapeutics, with prices ranging from Rs 1,500 and Rs 2,500 for complete maintenance, the source told TII.
Antivirus pills are considered as potential Gamechanger globally in the treatment of covid as remdesivir used until now being managed intravenously, and in hospital settings.
Mankind Pharma, which has been tied with BDR pharmacy.
Introducing the antivirus of Molulife (200 mg) in Delhi and other parts of other countries on Monday, said a company official.
Furthermore, Sun Pharma has provided an antivirus price around Rs 1,500 for full courses, and makes ‘Molxvir’ available on the market where there are more cases, and gradually throughout India.
The recommended dose of molnupiravir is 800 mg twice a day for five days.
Given the intense competition among market participants, maintenance costs will remain competitive and affordable for patients, experts say.
Molnupiravir, is also the first oral anti-covid pill approved by the British drug regulator, while recently food food and US drugs cleaned it for Covid-19 treatment which is light to medium to adults, and for those who are in place tall one.
Risk for development for severe diseases, including hospitalization or death.
Post a nod of USFDA, Indian Narcotics Controller gives permission for the use of Molnupiravir limited to the treatment of adult patients with 93% SPO2, and which has a high risk of disease development.
Previously in June, MSD signed a licensing agreement with five generic companies including Sun Pharma, Cipla, Torrent, Emcure, and Dr.
Reddy’s to produce and supply Molnupiravir in India, and to more than 100 low and medium-sized income countries.